Form 4: Cytosorbents Chief Medical Officer Exercises Subscription Rights, Acquires Shares and Warrants
SEC Form 4 Filing
Cytosorbents' Chief Medical Officer, Efthymios Deliargyris, exercised subscription rights, acquiring 16,233 shares of common stock and warrants.
Summary
- Efthymios Deliargyris, Chief Medical Officer of Cytosorbents, exercised subscription rights on January 17, 2025.
- This exercise resulted in the acquisition of 16,233 shares of Cytosorbents common stock at a price of $1.00 per unit, totaling $16,233.
- The transaction also included the acquisition of Series A and Series B warrants, each for 16,233 shares.
- The Series A warrants expire 45 days after the closing date of the rights offering, and the Series B warrants expire 90 days after the closing date.
- The exercise price of the warrants is based on the 5-day volume weighted average price of the company's common stock prior to their expiration, with minimum and maximum price limits.
- The reporting person also holds 403,025 shares of common stock, including unvested RSUs and shares owned directly.
Sentiment
Score: 7
Explanation: The document reflects a positive sentiment as it shows a key officer increasing their stake in the company, which is generally seen as a good sign. However, it is a routine filing and not a major event.
Positives
- The exercise of subscription rights by a key officer demonstrates confidence in the company's future.
- The acquisition of shares and warrants by the Chief Medical Officer aligns his interests with those of shareholders.
Risks
- The value of the warrants is dependent on the future performance of the company's stock price.
- The exercise price of the warrants is subject to market fluctuations.
Future Outlook
The value of the warrants is dependent on the future performance of the company's stock price.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the actions of company executives.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies, and this filing is consistent with standard reporting practices.
- The use of subscription rights and warrants is a typical method for companies to raise capital and incentivize employees.
- The vesting schedules for RSUs are also standard practice in the industry.
Stakeholder Impact
- The transaction may have a slightly positive impact on shareholders as it demonstrates confidence from a key officer.
- The exercise of warrants could potentially dilute existing shareholders if the warrants are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 04/09/2020 | Grant date of 120,000 RSUs that vest upon a Change in Control. |
| 07/07/2023 | Grant date of 55,000 RSUs that vest over two years. |
| 08/10/2022 | Grant date of 55,000 RSUs that vest upon a Change in Control. |
| 04/02/2024 | Grant date of 61,000 RSUs that vest over two years. |
| 12/09/2024 | Date of subscription rights certificates received. |
| 01/10/2025 | Closing date of the Rights Offering. |
| 01/17/2025 | Date of the transaction where subscription rights were exercised. |
| 01/22/2025 | Date of the SEC Form 4 filing. |
| 02/24/2025 | Expiration date of Series A Right Warrants. |
| 04/10/2025 | Expiration date of Series B Right Warrants. |
Keywords
Cytosorbents, Subscription Rights, Warrants, Common Stock, Insider Trading, SEC Form 4, Efthymios Deliargyris, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.